Pharmacyclics, Inc.

Novartis Ag

University of Pennsylvania

Jason A Dubovsky

John C Byrd

Natarajan Muthusamy

Amy Jo Johnson

David Miklos

Carl H June

Tarak D Mody

Joseph J Buggy

Jennifer Brogdon

Saar Gill

David Jonathan Glass

Marcela V Maus

Joan Mannick

Leon Murphy

David L Porter

Anna Vulpetti

Marco Ruella

Mariusz Wasik

Daniela Angst

Saad Kenderian

William Raj Sellers

Betty Chang

Joseph Fraietta

François Gessier

Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

Methods of treating and preventing graft versus host disease

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

TEC family kinase inhibitor adjuvant therapy

Growing community of inventors

Columbus, OH, United States of America

Jason A Dubovsky